Comments
Dr Reddy’s Laboratories Ltd will appeal the decision made by the US District Court for the District of New Jersey in a preliminary injunction hearing with respect to further sales and commercialisation of Dr Reddy’s Buprenorphine and Naloxone Sublingual Film within the US.
“The company disagrees with the court’s decision, and will vigorously appeal it,’’ it said in a release issued here on Saturday. Dr Reddy’s had announced the receipt of the approval on June 15, 2018 by one of its wholly-owned subsidiaries, from the US Food and Drug Administration (USFDA) for its Buprenorphine and Naloxone Sublingual film.
It’s an equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film in the US market.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.